X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14) 14
index medicus (14) 14
adult (11) 11
female (11) 11
male (11) 11
cancer (10) 10
middle aged (10) 10
oncology (10) 10
aged (9) 9
hematology (9) 9
treatment outcome (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
article (6) 6
chemotherapy (6) 6
drug therapy (6) 6
non-hodgkins-lymphoma (6) 6
adolescent (5) 5
b-cell lymphoma (5) 5
rituximab (5) 5
young adult (5) 5
active antiretroviral therapy (4) 4
lymphoma (4) 4
lymphoma, aids-related - drug therapy (4) 4
lymphomas (4) 4
aged, 80 and over (3) 3
aids (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
colleges & universities (3) 3
disease-free survival (3) 3
hiv (3) 3
lymphoma, b-cell - drug therapy (3) 3
prognosis (3) 3
recurrence (3) 3
retrospective studies (3) 3
stem cell transplantation (3) 3
survival analysis (3) 3
acquired immune deficiency syndrome--aids (2) 2
anti-retroviral agents - therapeutic use (2) 2
care and treatment (2) 2
clinical trials as topic (2) 2
complications and side effects (2) 2
cyclophosphamide (2) 2
dose-response relationship, drug (2) 2
doxorubicin - therapeutic use (2) 2
era (2) 2
etoposide (2) 2
experience (2) 2
gene rearrangement (2) 2
hematology, oncology and palliative medicine (2) 2
hemic and lymphatic diseases (2) 2
highly active antiretroviral therapy (2) 2
immunodeficiency (2) 2
intensive chemotherapy (2) 2
lymphoma, aids-related - complications (2) 2
lymphoma, aids-related - diagnosis (2) 2
lymphoma, aids-related - mortality (2) 2
lymphoma, large b-cell, diffuse - drug therapy (2) 2
maximum tolerated dose (2) 2
multivariate analysis (2) 2
neoplasm staging (2) 2
non-hodgkin lymphoma (2) 2
outcomes (2) 2
patients (2) 2
phase-ii trial (2) 2
poor-prognosis (2) 2
research (2) 2
risk factors (2) 2
survival (2) 2
transplantation, autologous (2) 2
trial (2) 2
tumors (2) 2
united-states (2) 2
virology (2) 2
100 (1) 1
3-weekly chop chemotherapy (1) 1
39 (1) 1
acquired immunodeficiency syndrome (1) 1
acquired immunodeficiency syndrome - complications (1) 1
acquired immunodeficiency syndrome - drug therapy (1) 1
adhd (1) 1
advance care planning (1) 1
advanced cancer (1) 1
agammaglobulinaemia tyrosine kinase (1) 1
age factors (1) 1
aggressive lymphomas (1) 1
aggressive non-hodgkin's lymphomas (1) 1
aid expression (1) 1
aids-related lymphoma (1) 1
alitretinoin (1) 1
alkylating agents (1) 1
alkylation (1) 1
analysis (1) 1
anemia (1) 1
anti-hiv agents - therapeutic use (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, murine-derived (1) 1
antibodies, monoclonal, murine-derived - therapeutic use (1) 1
antibody drug conjugate (1) 1
antimitotic agents (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 284 - 292
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2015, Volume 92, Issue 1, pp. 130 - 137
Purpose To report the long-term outcome and patterns of relapse of a large cohort of marginal zone lymphoma (MZL) patients treated with curative-intent... 
Radiology | Hematology, Oncology and Palliative Medicine | TRIAL | MULTICENTER | ONCOLOGY | TISSUE LYMPHOMA | RADIOTHERAPY | MALT LYMPHOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | STOMACH | Recurrence | Lymphoma, B-Cell, Marginal Zone - radiotherapy | Age Factors | Follow-Up Studies | Skin Neoplasms - radiotherapy | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Cause of Death | Lymphoma, B-Cell, Marginal Zone - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Lymphoma, B-Cell, Marginal Zone - pathology | Retrospective Studies | Neoplasms, Radiation-Induced | Orbital Neoplasms - radiotherapy | Skin Neoplasms - pathology | Stomach Neoplasms - radiotherapy | Orbital Neoplasms - pathology | Treatment Outcome | Head and Neck Neoplasms - pathology | Neoplasms, Second Primary - etiology | Disease-Free Survival | Head and Neck Neoplasms - radiotherapy | Breast Neoplasms - radiotherapy | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | Head and Neck Neoplasms - mortality | Orbital Neoplasms - mortality | Stomach Neoplasms - mortality | Antimitotic agents | Sects | Care and treatment | Radiation | Radiotherapy | Antineoplastic agents | Cancer | Tumors | Index Medicus | REVIEWS | HEAD | PATIENTS | MAMMARY GLANDS | THYROID | DEATH | RADIATION DOSES | SYMPTOMS | PATHOLOGY | LYMPHOMAS | RADIOLOGY AND NUCLEAR MEDICINE | NECK | SKIN | HAZARDS
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4119 - 4126
Purpose: The PARP inhibitor veliparib enhances the cytotoxicity of alkylating agents. This phase I study evaluated veliparib with the bifunctional alkylator... 
MULTIPLE-MYELOMA | REFRACTORY INDOLENT | MANTLE-CELL | POLY(ADP-RIBOSE) POLYMERASE | ONCOLOGY | MALIGNANT-LYMPHOMA | MULTICENTER PHASE-II | METASTATIC BREAST-CANCER | PLUS RITUXIMAB | NON-HODGKINS-LYMPHOMA | RELAPSED INDOLENT | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Bendamustine Hydrochloride - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rituximab - administration & dosage | Disease-Free Survival | Bendamustine Hydrochloride - administration & dosage | Maximum Tolerated Dose | Benzimidazoles - administration & dosage | Lymphoma, B-Cell - pathology | Adult | Female | Aged | Benzimidazoles - adverse effects | Lymphoma, B-Cell - drug therapy | Rituximab - adverse effects | Toxicity | Multiple myeloma | Cytotoxicity | Alkylation | Quality | Safety engineering | Hypophosphatemia | Expansion | Neutropenia | Hypertension | Thrombocytopenia | Leukopenia | Anemia | Alkylating agents | Rituximab | Poly(ADP-ribose) polymerase | Nausea | Pharmacology | Patients | Lymphoma | Inhibitors | Lymphocytes B | Lymphopenia | Experimental design | Lymphomas | Pharmacokinetics | Cancer | B-cell lymphoma | Index Medicus | veliparib | PARP | rituximab | lymphoma | bendamustine
Journal Article
Cancer Discovery, ISSN 2159-8274, 09/2017, Volume 7, Issue 9, pp. 1018 - 1029
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 08/2018, Volume 59, Issue 8, pp. 1851 - 1860
Drug-drug interactions between cART and chemotherapy may impact HIV and lymphoma control or lead to increased toxicities. No prospective comparative data... 
AIDS | HIV | dose-adjusted EPOCH | combination antiretroviral therapy | chemotherapy | HIV-associated lymphoma | SURVIVAL | IMMUNODEFICIENCY-VIRUS-INFECTION | CYCLOPHOSPHAMIDE | PREDNISONE CHEMOTHERAPY | B-CELL LYMPHOMA | ONCOLOGY | ERA | RITUXIMAB | VINCRISTINE | NON-HODGKINS-LYMPHOMA | POOLED ANALYSIS | HEMATOLOGY | Index Medicus
Journal Article
Journal of Cancer Epidemiology, ISSN 1687-8558, 2016, Volume 2016, pp. 2138259 - 9
The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy... 
Antiviral agents | Complications and side effects | Demographic aspects | HIV patients | Dosage and administration | Research | Drug therapy | Risk factors | Cancer
Journal Article
British Journal of Haematology, ISSN 0007-1048, 06/2016, Volume 173, Issue 6, pp. 857 - 866
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 02/2019, Volume 17, Issue 2, pp. 171 - 189
As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin's lymphoma,... 
UNITED-STATES | PHASE-II TRIAL | INTRALESIONAL VINBLASTINE | ONCOLOGY | RECONSTITUTION INFLAMMATORY SYNDROME | ACTIVE ANTIRETROVIRAL THERAPY | DEFINING OPPORTUNISTIC ILLNESSES | NON-HODGKINS-LYMPHOMA | HIV-INFECTED PERSONS | PEGYLATED-LIPOSOMAL DOXORUBICIN | HUMAN-IMMUNODEFICIENCY-VIRUS
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2005, Volume 130, Issue 5, pp. 691 - 699
Journal Article